Free Trial

Sutro Biopharma (STRO) Earnings Date, Estimates & Call Transcripts

Sutro Biopharma logo
$38.84 +1.15 (+3.06%)
As of 01:22 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Sutro Biopharma Earnings Summary

Sutro Biopharma announced Q3 2025 earnings on November 6, 2025, reporting an EPS of -$0.67, which missed analysts' consensus estimates of -$0.42 by $0.25. Quarterly revenue was reported to be $9.69 million, below the consensus estimate of $10.14 million. With a trailing EPS of -$26.10, Sutro Biopharma's earnings are expected to grow next year, from ($9.04) to ($7.92) per share.

Upcoming Q4
Earnings Date
May. 14Before Market OpensEstimated
Consensus EPS
(Nov. 6)
-$0.42
Actual EPS
(Nov. 6)
-$0.67 Missed By -$0.25
Actual Revenue
(Nov. 6)
$9.69M

Q3 2025 Earnings Resources

STRO Upcoming Earnings

Sutro Biopharma's Q1 2026 earnings is estimated for Thursday, May 14, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Get Sutro Biopharma Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sutro Biopharma and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

STRO Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

STRO Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Sutro Biopharma Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20262-$2.78-$2.53-$2.66
Q2 20262-$2.58-$1.52-$2.05
Q3 20262-$2.59-$1.34-$1.97
Q4 20262-$2.62-$1.34-$1.98
FY 2026 8 -$10.57 -$6.73 -$8.65
Q1 20271-$1.39-$1.39-$1.39
Q2 20271-$1.39-$1.39-$1.39
Q3 20271-$1.44-$1.44-$1.44
Q4 20271-$1.25-$1.25-$1.25

Sutro Biopharma Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
5/14/2026
(Estimated)
-------
11/6/2025Q3 2025-$0.42-$0.67 -$0.25-$6.70$10.14M$9.69M
8/7/2025Q2 2025-$3.90-$1.40+$2.50-$0.14$14.55M$63.74M
5/8/2025Q1 2025-$6.30-$9.10 -$2.80-$0.91$11.61M$17.40M
3/13/2025Q4 2024-$8.60-$29.60 -$21.00-$0.89$10.44M$14.00M
8/13/2024Q2 2024-$7.90-$5.90+$2.00-$0.59$26.28M$25.71M
5/13/2024Q1 2024-$9.20-$9.50 -$0.30-$0.95$11.57M$13.01M

Data powered by Fiscal.ai.

Sutro Biopharma Earnings - Frequently Asked Questions

Sutro Biopharma has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 14th, 2026 based off last year's report dates. Learn more on STRO's earnings history.

In the previous quarter, Sutro Biopharma (NASDAQ:STRO) missed the analysts' consensus estimate of ($0.42) by $0.25 with a reported earnings per share (EPS) of ($0.67). Learn more on analysts' earnings estimate vs. STRO's actual earnings.

Sutro Biopharma (NASDAQ:STRO) has a recorded annual revenue of $102.48 million.

Sutro Biopharma (NASDAQ:STRO) has a recorded net income of -$191.09 million. STRO has generated -$26.10 earnings per share over the last four quarters.

Sutro Biopharma's earnings are expected to grow from ($9.04) per share to ($7.92) per share in the next year.


This page (NASDAQ:STRO) was last updated on 5/7/2026 by MarketBeat.com Staff.
From Our Partners